Evidence map›Paper›PMID 40487637›Full record

ArticleActa pharmaceutica Sinica. B2025

A critical role for

Manyun Chen, Yilei Peng, Yuhui Hu, Zhiqiang Kang, Ting Chen, Yulong Zhang, Xiaoping Chen, Qing Li, Zuyi Yuan, Yue Wu and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta pharmaceutica Sinica. B, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. The Role of Ceramides in Metabolic and Cardiovascular Diseases.Journal of cardiovascular development and disease · 2026
    Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Manyun ChenDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, China.
Yilei PengDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, China.
Yuhui HuDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, China.
Zhiqiang KangZhengzhou Central Hospital Affiliated to Zhengzhou University, Zhengzhou University, Zhengzhou 450007, China.
Ting ChenKey Laboratory of Hunan Province for Integrated Traditional Chinese and Western Medicine on Prevention and Treatment of Cardio-Cerebral Diseases, Hunan University of Chinese Medicine, Changsha 410208, China.
Yulong ZhangDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, China.
Xiaoping ChenDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, China.
Qing LiDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, China.
Zuyi YuanDepartment of Cardiology, Cardiovascular Research Center, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China.
Yue WuDepartment of Cardiology, Cardiovascular Research Center, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China.
Heng XuDepartment of Laboratory Medicine, National Key Laboratory of Biotherapy/ Collaborative Innovation Center of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, China.
Gan ZhouDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, China.
Tao LiuShenzhen Center for Chronic Disease Control and Prevention, Shenzhen 518020, China.
Honghao ZhouDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, China.
Chunsu YuanDepartment of Anesthesia and Critical Care, University of Chicago, Chicago, IL 60637, USA.
Weihua HuangDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, China.
Wei ZhangDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Metformin has been demonstrated to attenuate hyperglycaemia by modulating the gut microbiota. However, the mechanisms through which the microbiome mediates metformin monotherapy failure (MMF) are unclear. Herein, in a prospective clinical cohort study of newly diagnosed type 2 diabetes mellitus (T2DM) patients treated with metformin monotherapy, metagenomic sequencing of faecal samples revealed that

Indexed as

CeramideDeconjugated bile acidsFarnesoid X receptorGut microbiotaMetformin resistanceMitochondrial dysfunctionOxidative phosphorylationThermogenesis

Identifiers

PMID40487637
PMCPMC12145038

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.